Alison Tang

AstraZeneca (United Kingdom)

Papers

1

Total Citations

13

H-Index

1

About

Dr. Alison Tang is a leading bioprocess engineer whose work is shaping the future of biopharmaceutical manufacturing, with a particular focus on virus filtration and high-throughput process development. Her most influential contribution, the 2020 paper "A novel high-throughput process development screening tool for virus filtration," has garnered 13 citations and addresses a critical bottleneck in the industry: the reliance on large-volume, costly bench-scale models for virus clearance studies. Tang’s innovative screening tool enables rapid, small-scale evaluation of filtration performance, drastically reducing the material and time required for process optimization. This breakthrough not only accelerates the development of safer, more efficient biologics—such as monoclonal antibodies—but also lowers the financial barriers for emerging therapies. By bridging the gap between laboratory research and commercial manufacturing, Dr. Tang’s work has been recognized as a pivotal advancement in downstream processing. Her achievements underscore a commitment to practical, scalable solutions that enhance both safety and productivity in the production of life-saving medicines.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
A novel high-throughput process development screening tool for virus filtration
13 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago